The Hematologist

September October 2017 Vol 14 Issue 5

September-October 2017, Volume 14, Issue 5

Features

back to top

Diffusion

back to top

Ask the Hematologist

back to top

Mini Review

back to top

Clinical Trials Corner

  • The Potential Utility of Immunotherapy for AMLAugust 08, 2017

    Dr. Abdel-Wahab and Dr. Taylor look at a study that evaluates the safety of combining the anti-PD-L1 antibody atezolizumab with the novel hypomethylating agent guadecitabine in older adults with AML not eligible for standard induction therapy.

back to top

Profiles

back to top

President's Column

back to top

Letters to the Editor

back to top

Image Challenges

back to top